Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 554.46 M
The data is delayed by 15 minutes.
Description: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdo
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||57.22 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-90.4%||Sales Growth - Q/Q||-91.2%||P/E|
|P/E To EPS Growth||P/S||19.17||P/BV||2.54||Price/Cash Per Share|
|Price/Free Cash Flow||-14.75||ROA||-43.21%||ROE||-50.12%||ROI|
|Current Ratio||20.83||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||-378.54%||Net Profit Margin||-378.3%||Dividend Payout Ratio|
|Cash From Financing Activities||117.28 M||Cash From Investing Activities||-40.16 M||Cash From Operating Activities||-22.71 M||Gross Profit|
|Net Profit||-61.33 M||Operating Profit||-61.38 M||Total Assets||253.27 M||Total Current Assets||247.4 M|
|Total Current Liabilities||11.88 M||Total Debt||1.68 M||Total Liabilities||34.89 M||Total Revenue||910 K|
|High 52 week||15.12||Low 52 week||5.22||Last close||11.5||Last change||-5.66%|
|RSI||36.56||Average true range||0.81||Beta||1.92||Volume||427.11 K|
|Simple moving average 20 days||-9.78%||Simple moving average 50 days||-12.35%||Simple moving average 200 days||4.44%|
|Performance Week||-5.74%||Performance Month||-15.07%||Performance Quart||-5.12%||Performance Half||-3.44%|
|Performance Year||15.58%||Performance Year-to-date||86.69%||Volatility daily||3.62%||Volatility weekly||8.09%|
|Volatility monthly||16.57%||Volatility yearly||57.41%||Relative Volume||342.21%||Average Volume||886.3 K|
|New High||New Low|
2019-09-08 09:30:01 | Epizyme EPZM Up 7% Since Last Earnings Report: Can It Continue?
2019-08-29 06:30:00 | Epizyme to Participate in Upcoming September Conferences
2019-08-16 12:32:14 | How Should Investors Feel About Epizyme, Inc.'s NASDAQ:EPZM CEO Pay?
2019-08-15 09:17:01 | Epizyme EPZM Focuses on Developing Lead Drug Tazemetostat
2019-08-12 08:37:12 | Epizyme EPZM Q2 Loss In Line, Revenues Beat Estimates
2019-08-09 07:55:11 | Epizyme EPZM Reports Q2 Loss, Tops Revenue Estimates
2019-08-09 06:30:00 | Epizyme Reports Business Progress and Second Quarter 2019 Results
2019-08-08 10:45:02 | Immunomedics IMMU Posts Wider-Than-Expected Loss in Q2
2019-08-08 10:15:02 | Horizon Therapeutics' HZNP Q2 Earnings Beat Estimates
2019-08-08 09:26:01 | Catalyst's CPRX Q2 Earnings and Revenues Beat Estimates
2019-08-06 06:30:00 | Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference
2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma
2019-07-25 10:33:02 | Analysts Estimate Epizyme EPZM to Report a Decline in Earnings: What to Look Out for
2019-07-12 16:53:00 | Here's Why Epizyme Rose 103.7% in the First Half of 2019
2019-06-24 17:53:09 | Epizyme Announces Positive Interim Data on Lead Candidate
2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
2019-06-11 18:57:32 | Hedge Funds Have Never Been This Bullish On Epizyme Inc EPZM
2019-06-05 09:30:01 | Why Is Epizyme EPZM Up 10.9% Since Last Earnings Report?
2019-05-31 10:46:02 | Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
2019-05-31 05:57:33 | Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
2019-05-30 05:51:09 | Will Epizyme to Surge Higher?
2019-05-29 06:30:00 | Epizyme to Present at Jefferies 2019 Healthcare Conference
2019-05-28 09:02:01 | Epizyme EPZM Shares Surge More Than 100% YTD: Here's Why?
2019-05-09 20:10:46 | Hedge Funds Have Never Been This Bullish On Epizyme Inc EPZM
2019-05-06 07:45:11 | Epizyme EPZM Reports Q1 Loss, Tops Revenue Estimates
2019-05-06 06:35:23 | Epizyme: 1Q Earnings Snapshot
2019-05-06 06:30:00 | Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results
2019-03-28 09:30:01 | Why Is Epizyme EPZM Down 14.4% Since Last Earnings Report?
2019-03-08 12:14:36 | Does Epizyme, Inc.’s NASDAQ:EPZM CEO Salary Compare Well With Others?
2019-03-05 06:30:00 | Epizyme Announces Presentations at Upcoming March Investor Conferences
2019-02-27 10:14:03 | Epizyme EPZM Reports Narrower-Than-Expected Loss in Q4
2019-02-26 18:13:32 | Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT
2019-02-14 12:58:05 | 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
2019-02-12 07:35:00 | New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
2019-01-07 18:14:11 | Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
2019-01-07 08:09:51 | Why Epizyme Stock Rose ~33% on January 4